Atticus Medical

A Persistent Public Health Challenge: Head Lice Infestation in Primary School Children A recent systematic review has brought to light the ongoing challenge of head lice infestation among primary school children in low- and middle-income countries (https://rdcu.be/dRogX). We also know that each year there are about 9 million new cases of headlice in the USA alone. Head lice continue to be a significant public health concern, impacting both the well-being and academic performance of affected children worldwide. Key Findings of this study are: - Girls were 3.71 times more likely to have head lice than boys. - Children with a history of infestation were 4.51 times more likely to experience re-infestation. These findings underscore the urgent need for innovative treatments and targeted interventions. At Atticus Medical, we are committed to addressing this challenge by developing moxidectin as a new and effective treatment for head lice. Moxidectin’s potential to provide a more reliable and long-lasting solution could transform the approach to managing head lice in resource-limited settings in high-, middle- and low-income countries where the burden is greatest. Together, we can reduce the burden of head lice infestation and improve the health and education outcomes of children worldwide.

🔍 Scabies: A Global Health Concern Scabies is often overlooked, yet it affects millions of people worldwide, cutting across both high- and low-income countries. This highly contagious skin condition is caused by a tiny mite and can cause severe discomfort, social stigma, and complications if left untreated. Recent outbreaks, such as the one currently impacting four hospitals in NSW, highlight the ongoing and pervasive nature of this issue https://lnkd.in/gs2C3F_F. At Atticus Medical, we are committed to addressing this issue head-on. Our team is working to develop a new medicine specifically for treating scabies and ensuring its accessibility for everyone, regardless of economic status. In our collaboration with Medicines Development for Global Health we are making strides in the fight against scabies, improving health outcomes, and enhancing the quality of life for countless individuals globally. Your support and awareness can help us drive positive change. #GlobalHealth #Scabies #AtticusMedical #MDGH

Great progress on this important study MDGH. Well done.

Exciting news from the team at Medicines Development for Global Health. Great to see achievement of this milestone.

8 July marked World Skin Health Day, a global initiative from The International League of Dermatological Societies and The International Society of Dermatology. Its purpose is to educate about the significance of skin health and to encourage discussion and actions that work towards improving skin health.   At Medicines Development for Global Health, we are focused on developing new medicines for neglected tropical diseases – many of which have significant skin manifestations. These diseases can cause massive discomfort, and often bring lasting stigma and long-term disability to those who are affected. Find out more about our work developing new medicines for river blindness, lymphatic filariasis, leprosy, and scabies (in partnership with Atticus Medical): visit https://lnkd.in/gZf9gyj #moxidectin #dovramilast #beatNTDs #scabies #onchocerciasis #lymphaticfilariasis #leprosy #GlobalHealth #clinicalresearch

According to recent news reports from the United Kingdom, cases of scabies have doubled in the past year. Healthcare professionals are concerned that failure to recognise and treat the condition quickly, coupled with a shortage of key medications will exacerbate this public health issue. Human scabies is a highly contagious skin condition caused by a tiny mite, known as Sarcoptes scabiei. The World Health Organization considers it to be one of the most common skin conditions worldwide, with at least 200 million people suffering from the condition at any given time. Scabies causes intense itching; repeated scratching breaks the skin leading to skin sores, and can progress to serious blood infections, kidney damage and even heart disease. Children, older people and disadvantaged communities are most at risk. Current treatments for scabies are cumbersome, inconvenient and messy. At Atticus Medical and Medicines Development for Global Health we are investigating the potential for moxidectin as a single-dose oral medication for scabies. Our current Phase 2 trial started last year and is actively recruiting people with scabies at sites in the United States and Latin America, with more sites planned. Read more: https://lnkd.in/ggN8avVh Find out more about our scabies program at https://lnkd.in/gqsGr6_a #moxidectin #beatNTDs #scabies #GlobalHealth

Atticus Medical and Medicines Development for Global Health announce that clearance has been received from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for moxidectin for scabies. Moxidectin is in Phase 2 clinical trials as a potential single dose treatment for this debilitating disease and this clearance allows sites in the USA to be included in the study.   Clearing the IND hurdle is a significant milestone in the development of moxidectin to address neglected diseases. Scabies is a contagious skin infestation that has often been neglected by the global research community. It is caused by the Sarcoptes scabiei mite, and affects hundreds of millions of people worldwide, predominantly but not exclusively in resource-limited settings.   The IND is supported by data from a recently completed scabies clinical trial conducted in Australia and Europe, and data reviewed by the FDA as part of their 2018 marketing authorisation of moxidectin for the treatment river blindness (onchocerciasis), in adults and adolescents 12 years and older.   The clinical trial cleared under this IND pushes the program further into establishing the role of moxidectin as a potential oral treatment option for people suffering from scabies. For more information about Atticus Medical, please visit www.atticusmed.com. For more information about scabies, please visit https://lnkd.in/gr5Gg-nm. #moxidectin #scabies #investors #clinicaltrials #globalhealth

Atticus Medical and Medicines Development for Global Health announce that the first patient has been enrolled in a Phase 2b study of moxidectin in scabies (MDGH-MOX-2002; NCT05875441). The study is being conducted in partnership with Medicines Development for Global Health and is being funded by Atticus Medical. This multi-center, global study aims to investigate the efficacy and safety of different doses of moxidectin for achieving complete cure within 28 days in adults with scabies.    Scabies is one of the most common contagious skin conditions in the world and can have a profound impact on individuals and communities. It is caused by a tiny mite that burrows into the skin, resulting in an itchy rash that can cause serious discomfort and impacts on quality of life. Repeated scratching can lead to more serious consequences, including bacterial skin infections with potential to contribute to kidney disease and heart valve damage. Scabies spreads easily in settings where people live in close contact, and it is estimated that as many as 200 million people suffer from the infestation at any given time. Current treatments are cumbersome because they often require repeat dosing and commonly involve the messy application of topical medications over the entire body. If successful, moxidectin could be a single oral dose treatment that would simplify the treatment of scabies and significantly improve patients’ quality of life.    Read the full release here: https://lnkd.in/dj9mqMEc